Evidence Grade C — Moderate human evidence. 31 published studies, 18 human. 1 registered clinical trial.
Medically reviewed by a licensed medical professional
CJC-1295 (without DAC) is a synthetic modified fragment of growth hormone-releasing hormone designed to resist enzymatic breakdown, stimulating the pituitary gland to release growth hormone. It has no approval from any regulatory agency and no Phase III trials have been completed. It is widely available through unregulated sources, often combined with ipamorelin.
CJC-1295 is also known by these brand and alternate names:
31 published studies: 18 human, 5 animal, 4 in-vitro, 8 reviews
CJC-1295 (without DAC) has no marketing authorisation from any regulatory agency. Limited Phase I pharmacokinetic data showed increased growth hormone levels following single injections. No Phase III trials have been conducted.
CJC-1295 is widely available through unregulated channels, often in combination with ipamorelin. These combinations have no clinical trial support. Products from unregulated sources lack pharmaceutical quality assurance. The compound should be distinguished from CJC-1295 DAC (#90), which has a different pharmacokinetic profile.
Research suggests CJC-1295 binds the GHRH receptor on pituitary cells, stimulating growth hormone release. The four amino acid substitutions protect the peptide from the enzyme DPP-IV that rapidly degrades native GHRH. These observations come from limited early-phase human pharmacokinetic data and animal studies. The clinical significance of these effects has not been established in controlled trials.
Research is limited to early-phase pharmacokinetic data showing that CJC-1295 increases growth hormone levels after single injections. No efficacy trials have been conducted for any clinical outcome. The commonly used combination with ipamorelin has no clinical trial support whatsoever. Safety concerns include potential pituitary desensitisation with repeated use, unknown effects of sustained IGF-1 elevation (including theoretical cancer risk), and cortisol co-stimulation. A death was reported in a 2006 clinical trial of the DAC (Drug Affinity Complex) version, though causality was not established. Products from unregulated sources lack pharmaceutical quality assurance.
PeptideTrace tracks 1 registered clinical trial for CJC-1295 sourced from ClinicalTrials.gov.
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
CJC-1295 (modified GRF 1-29) is a synthetic 30-amino-acid GHRH analogue, MW ~3,367 Da. First 29 AA of GHRH with four substitutions (D-Ala2, Gln8, Ala15, Met(O)27) for DPP-IV/protease resistance. Without DAC: half-life ~30 minutes. Not approved. Often combined with ipamorelin in grey-market.
Research suggests binding to GHRH-R (class B GPCR) on pituitary somatotrophs. Gs/cAMP/PKA signaling stimulates pulsatile GH release mirroring physiology. Four substitutions protect against DPP-IV cleavage. Animal studies indicate increased GH pulse amplitude without altered frequency.
No marketing authorization. Teichman et al. (JCEM 2006; N=21): single SC injection increased GH 2-10-fold for up to 6 hours. No Phase III. Grey-market: 100-300 mcg SC with ipamorelin, not clinically validated.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 44 vendor listings
View pricing data across vendors and countries for CJC-1295
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes. Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
MGF has no marketing authorisation. No human clinical trials have been conducted. The evidence base consists of animal studies and cell culture experiments. A single mouse study reported increased muscle fibre size after intramuscular injection. The compound's very short half-life (estimated minutes) in its native form has led to the development of PEGylated versions (PEG-MGF, #105) in unregulated channels, though this creates a pharmacologically distinct molecule. Products available through unregulated channels lack pharmaceutical quality assurance.
Tesamorelin is marketed as Egrifta SV (approved November 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In clinical trials, it reduced visceral fat by approximately 15% compared to a 5% increase with placebo, and this reduction was sustained with continued treatment. Tesamorelin occupies a unique niche — it is the only approved GHRH analogue and the only medication specifically approved for HIV-associated lipodystrophy. Beyond its approved indication, it has attracted research interest for potential effects on liver fat, cognitive function, and peripheral neuropathy. Fat reduction reverses when treatment stops, and it is not approved for general weight loss or body composition purposes.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
